Mayne Pharma Group Ltd
ASX:MYX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.81
7.37
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Mayne Pharma Group Ltd
Mayne Pharma Group Ltd
Capital Expenditures
Mayne Pharma Group Ltd
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Capital Expenditures
-AU$20.9m
|
CAGR 3-Years
6%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Capital Expenditures
-AU$25k
|
CAGR 3-Years
-46%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
5%
|
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Capital Expenditures
-AU$18m
|
CAGR 3-Years
-1 195%
|
CAGR 5-Years
-323%
|
CAGR 10-Years
N/A
|
|
|
Probiotec Ltd
ASX:PBP
|
Capital Expenditures
-AU$10.8m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-5%
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Capital Expenditures
-AU$583k
|
CAGR 3-Years
-64%
|
CAGR 5-Years
-72%
|
CAGR 10-Years
2%
|
|
|
Arovella Therapeutics Ltd
ASX:ALA
|
Capital Expenditures
-AU$129.3k
|
CAGR 3-Years
37%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
Mayne Pharma Group Ltd
Glance View
Mayne Pharma Group Ltd. engages in the development and manufacture of proprietary and generic products. The company is headquartered in Adelaide, South Australia. The company went IPO on 2007-06-29. The Company’s segments include Generic Products (GPD), Specialty Products (SPD), Metrics Contract Services (MCS), and Mayne Pharma International (MPI). The GPD segment is engaged in the distribution of generic pharmaceutical products in the United States. GPD segment engaged in the distribution of generic pharmaceutical products in the United States. MCS segment is providing contract pharmaceutical development and manufacturing services to third party customers principally in the United States. SPD segment is distributing specialty pharmaceutical products in the United States. MPI segment manufactures and sells branded and generic pharmaceutical products globally and provisions of contract manufacturing services to third party customers within Australia.
See Also
What is Mayne Pharma Group Ltd's Capital Expenditures?
Capital Expenditures
-20.9m
AUD
Based on the financial report for Jun 30, 2024, Mayne Pharma Group Ltd's Capital Expenditures amounts to -20.9m AUD.
What is Mayne Pharma Group Ltd's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
24%
Over the last year, the Capital Expenditures growth was 90%. The average annual Capital Expenditures growth rates for Mayne Pharma Group Ltd have been 6% over the past three years , 24% over the past five years .
You don't have any saved screeners yet
